We are weaving a canvas of academic and industrial partners to jointly develop a technological platform that can impact significantly the future of cancer immunotherapy. To do so, we are keen to create pluridisciplinary interactions between the relevant fields of basic and translational research, as well as business development and marketing.
The current IMcoMET portfolio offers opportunities for early investors at both seed and serie A stages depending on the project. Don’t hesitate to reach out using the form below.
Who we are
IMcoMET is young start-up biotech company in the field of cancer immunotherapy. We are building an R&D ecosystem structured around 3 main pillars that are at various technological readiness levels
Find out more on IMcoMET and its collaborators.
We are driving our business by keeping a healthy balance in our innovation funnel portfolio. To do so we focus on different projects at various TRL stages.
Read more about their details.